Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Calcifediol Anhydrous. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | VDR known ✓ | P11473 | 8/20 | 0.82 |
| ▸ | MAPT | P10636 | 5/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 1.00 |
| ▸ | SREBF1 | P36956 | 1/20 | 1.00 |
| ▸ | MEN1 | O00255 | 3/20 | 0.82 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.82 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.82 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.82 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.82 |
| ▸ | PGR | P06401 | 2/20 | 0.82 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.82 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.82 |
| ▸ | CDC25A | P30304 | 1/20 | 0.82 |
| ▸ | HSPD1 | P10809 | 1/20 | 0.82 |
| ▸ | HPGD | P15428 | 1/20 | 0.82 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.82 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.82 |
| ▸ | GLRA1 | P23415 | 1/20 | 0.82 |
| ▸ | DRD3 | P35462 | 1/20 | 0.82 |
| ▸ | HSPE1 | P61604 | 1/20 | 0.82 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Calcifediol Anhydrous SCHEMBL10018928 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL13301741 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL9933434 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL3296 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24102681 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL5614025 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24051907 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL14112503 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL24571935 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 | |
| Calcifediol Anhydrous SCHEMBL22403256 | 1.00 | MAPT (1.00) | MAPTSMN1; SMN2SREBF1VDRMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3152185-B1 | METHOD AND USAGE OF A SALT FOR SEPARATING EPIMERS BY ION MOBILITY SPECTROMETRY | ROCHE DIAGNOSTICS GMBH (DE) | 2023-10-04 | — | — | EP | claimed |
| EP-3805224-B1 | ANALYSIS METHOD OF DIENE COMPOUND AND PRODUCTION METHOD OF ENE COMPOUND | JEOL LTD (JP) | 2023-04-12 | — | — | EP | claimed |
| EP-4623289-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | F. Hoffmann-La Roche AG (CH) | 2025-10-01 | — | — | EP | disclosed |
| US-12272440-B2 | Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns | I.D. THERAPEUTICS LLC (US) | 2025-04-08 | — | — | US | disclosed |
| EP-4437338-A1 | METHOD FOR DETERMINING AN ANALYTE OF INTEREST BY FREQUENCY DETECTION | F. Hoffmann-La Roche AG (CH) | 2024-10-02 | — | — | EP | disclosed |
| CN-111983244-B | Detection method and detection kit for four vitamins in dried blood spots | 天津国科医疗科技发展有限公司 | 2024-10-01 | — | — | CN | disclosed |
| US-20240249821-A1 | METHODS, SYSTEMS, AND APPARATUS FOR OPTIMIZING EFFECTS OF TREATMENT WITH MEDICATION USING MEDICATION COMPLIANCE PATTERNS | I.D. THERAPEUTICS LLC (US) | 2024-07-25 | — | — | US | disclosed |
| WO-2024110422-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | F. HOFFMANN-LA ROCHE AG (CH) | 2024-05-30 | — | — | WO | disclosed |
| CN-118090988-A | Method for detecting total amount of 25-hydroxy vitamin D in breast milk | 北京三元食品股份有限公司 | 2024-05-28 | — | — | CN | disclosed |
| US-11942209-B2 | Methods, systems, and apparatus for optimizing effects of treatment with medication using medication compliance patterns | I.D. THERAPEUTICS LLC (US) | 2024-03-26 | — | — | US | disclosed |
| US-20230420240-A1 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | ROCHE DIAGNOSTICS OPERATIONS, INC. | 2023-12-28 | — | — | US | disclosed |
| EP-4154009-A1 | REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| EP-4153572-A1 | IMIDAZOLIUM REAGENT FOR MASS SPECTROMETRY | F. Hoffmann-La Roche AG (CH) | 2023-03-29 | — | — | EP | disclosed |
| WO-2022136286-A1 | AUTOMATED CLINICAL DIAGNOSTIC SYSTEM AND METHOD | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-30 | — | — | WO | disclosed |
| WO-2022117604-A1 | DETECTION OF AN ANALYTE OF INTEREST BY CROSS SPRAY ESI MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2022-06-09 | — | — | WO | disclosed |
| WO-2022084362-A1 | DETECTION OF AN ANALYTE OF INTEREST BY NANOESI MASS SPECTROMETRY | F. HOFFMANN-LA ROCHE AG (CH) | 2022-04-28 | — | — | WO | disclosed |
| WO-2022034018-A1 | METHOD FOR DETERMINING AT LEAST ONE ANALYTE OF INTEREST | F. HOFFMANN-LA ROCHE AG (CH) | 2022-02-17 | — | — | WO | disclosed |
| CN-111983244-A | Detection method and detection kit for four vitamins in dry blood spots | 天津国科医工科技发展有限公司 | 2020-11-24 | — | — | CN | disclosed |
| US-20100144671-A1 | Compositions and Methods for Cancer Treatment | WOMEN AND INFANTS HOSPITAL OF RI, INC. (US) | 2010-06-10 | — | — | US | disclosed |
| WO-2006096555-A1 | COMPOSITIONS AND METHODS FOR CANCER TREATMENT | WOMEN AND INFANTS HOSPITAL OF RI, INC. (US) | 2006-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144671-A1 | Compositions and Methods for Cancer Treatment | CYP24A1, BAX, BAD | VDR 4/4885MAPT 3125/4885SMN1; SMN2 1643/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.